Kebilidi (eladocagene exuparvovec-tneq) - MEDICAID - SOUTH CAROLINA

Kebilidi (eladocagene exuparvovec‑tneq) gene therapy is covered for treatment of aromatic L‑amino acid decarboxylase (AADC) deficiency and is administered as four intraputaminal infusions in a single stereotactic neurosurgical procedure to deliver the DDC gene and restore AADC enzyme expression. Coverage is limited to Humana members with confirmed biallelic DDC mutations (typically symptomatic patients aged 16 months through 10 years), available as a single one‑time lifetime dose, and is contingent on meeting the plan’s requirements and medical review/prior authorization (Corporate Transplant Department).

"Aromatic L‑amino acid decarboxylase (AADC) deficiency, a rare autosomal recessive neurometabolic condition characterized by decreased synthesis of serotonin and catecholamines (adrenaline, dopamine..."

Sign up to see full coverage criteria, indications, and limitations.